Abstract:Targeted delivery to the diseased cell or tissue is the key to the successful clinical use of nucleic acid drugs. In particular, delivery of microRNA-140 (miRNA-140, miR-140) into chondrocytes across the dense, nonvascular extracellular matrix of cartilage remains a major challenge. Here, we report the chondrocyte-targeting exosomes as vehicles for the delivery of miR-140 into chondrocytes as a new treatment for osteoarthritis (OA). By fusing a chondrocyte-affinity peptide (CAP) with the lysosome-associated membrane glycoprotein 2b protein on the surface of exosomes, we acquire CAP-exosomes that can efficiently encapsulate miR-140, specifically enter, and deliver the cargo into chondrocytes in vitro. CAP-exosomes, in contrast to nontagged exosome vesicles, are retained in the joints after intra-articular injection with minimal diffusion in vivo. CAP-exosomes also deliver miR-140 to deep cartilage regions through the dense mesochondrium, inhibit cartilage-degrading proteases, and alleviate OA progression in a rat model, pointing toward a potential organelle-based, cell-free therapy of OA.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c10458?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c10458</a>.List of primers used for cloning, reverse transcription-polymerase chain reaction (RT-PCR), and real-time quantitative RT-PCR in this work; list of antibodies used in this work; overexpression of GFP-Lamp2b or CAP-GFP-Lamp2b in dendritic cells showing green puncta; selective entrance of CAP-GFP-exosomes to chondrocytes but not SF-MSCs; quantification of the loading efficiency of exosomes; CAP-exosomes showed increased delivery of miRNA-140 to chondrocytes than exosomes without the CAP signal; analysis of the reporter gene activity in chondrocytes confirms that CAP-exosome/miR-140 directly targets the predicted binding sites in the MMP-13 and Adamts-5 3′UTR; images of safranin O and fast green staining of cartilages under different treatments; and toxicity of the exosome treatment to major organs (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c10458/suppl_file/am0c10458_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display

Phage Display Identified Peptide with Selectivity for Human Osteoarthritic Chondrocytes

Chondrocyte affinity peptide modified PAMAM conjugate as a nanoplatform for targeting and retention in cartilage.

Reiterated Targeting Peptides on the Nanoparticle Surface Significantly Promote Targeted Vascular Endothelial Growth Factor Gene Delivery to Stem Cells.

Cartilage-Targeting Mrna-Lipid Nanoparticles Rescue Perifocal Apoptotic Chondrocytes for Integrative Cartilage Repair

Capra cartilage-derived peptide delivery via carbon nano-dots for cartilage regeneration

Cartilage-Derived Progenitor Cell-Laden Injectable Hydrogel-An Approach for Cartilage Tissue Regeneration

Charge‐Reversed Exosomes for Targeted Gene Delivery to Cartilage for Osteoarthritis Treatment

Chondrocyte-Targeted MicroRNA Delivery by Engineered Exosomes toward a Cell-Free Osteoarthritis Therapy

Co‐Polymer Carrier with Dual Advantages of Cartilage‐Penetrating and Targeting Improves Delivery and Efficacy of microRNA Treatment of Osteoarthritis

Nanopolymers Delivery of the Bone Morphogenetic Protein-4 Plasmid to Mesenchymal Stem Cells Promotes Articular Cartilage Repair in Vitro and in Vivo

Chondrocyte-specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment

In Vivo and in Vitro Cartilage Transfection by a Non-Viral Gene Delivery System

Nanoparticle Functionalization with Genetically-Engineered Mesenchymal Stem Cell Membrane for Targeted Drug Delivery and Enhanced Cartilage Protection

Promoting chondrogenesis by targeted delivery to the degenerating cartilage in early treatment of osteoarthritis

Chondrocyte-Targeted Delivery System of Sortase A-Engineered Extracellular Vesicles Silencing MMP13 for Osteoarthritis Therapy

Surface Functionalization of Exosomes for Chondrocyte-Targeted Sirna Delivery and Cartilage Regeneration

Thermosensitive Hydrogel Based on PEO–PPO–PEO Poloxamers for a Controlled In Situ Release of Recombinant Adeno‐Associated Viral Vectors for Effective Gene Therapy of Cartilage Defects

Development of Targeted Nanoscale Drug Delivery System for Osteoarthritic Cartilage Tissue

Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis

One-Step Formation of Chondrocytes Through Direct Reprogramming Via Polysaccharide-Based Gene Delivery